Erratum to: "A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1" [J Immunother Cancer. (2016), 4, (55)], DOI: 10.1186/s40425-016-0157-6;A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1

Journal for ImmunoTherapy of Cancer

Volumn 4, Issue 1, 2016, Pages

  Uemura, Marc ^a   Faisal, Faa'k ^a   Haymaker, Cara ^a   McQuail, Natalie ^a   Sirmans, Elizabeth ^a   Hudgens, Courtney W ^a   Barbara, Lydia ^a   Bernatchez, Chantale ^a   Curry, Jonathan L ^a   Hwu, Patrick ^a   Tetzlaff, Michael T ^a   Diab, Adi ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; STEROID; TRAMETINIB;

ACANTHOLYSIS; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; ERYTHEMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INFLAMMATORY INFILTRATE; KERATINOCYTE; MALE; METASTATIC MELANOMA; PRIORITY JOURNAL; RASH; SKIN BIOPSY; TH2 CELL; TRANSIENT ACANTHOLYTIC DERMATOSIS;

EID: 84997712026     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-017-0208-7     Document Type: Erratum

References (15)

1. Grover RW. Transient acantholytic dermatosis. Arch Dermatol. 1970;101(4):426-34.
2. Chalet M, Grover R, Ackerman AB. Transient acantholytic dermatosis: a reevaluation. Arch Dermatol. 1977;113(4):431-5.
3. Davis MD, Dinneen AM, Landa N, Gibson LE. Grover's disease: clinicopathologic review of 72 cases. Mayo Clin Proc. 1999;74(3):229-34.
4. Guana AL, Cohen PR. Transient acantholytic dermatosis in oncology patients. J Clin Oncol. 1994;12(8):1703-9.
5. Anforth R, Fernandez-Penas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 2013;14(1):e11-18.
6. Moon HR, Lee JH, Rhee DY, Won CH, Chang SE, Lee MW, Choi JH, Moon KC. Grover's Disease in a Liver Transplant Patient. Ann Dermatol. 2014;26(1):117-8.
7. Mahler SJ, De Villez RL, Pulitzer DR. Transient acantholytic dermatosis induced by recombinant human interleukin 4. J Am Acad Dermatol. 1993;29(2 Pt 1):206-9.
8. Munoz J, Guillot B, Girard C, Dereure O, Du-Thanh A. First report of ipilimumab-induced Grover disease. Br J Dermatol. 2014;171(5):1236-7.
9. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
10. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-26.
11. Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity. 1997;7(6):885-95.
12. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol. 2010;37(5):473-84.
13. Callahan MK, Yang A, Tandon S, Xu Y, Subudhi SK, Roman RA, Heine AI, Pogoriler E, Kuk D, Panageas K et al. Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis. J Clin Oncol. 29:2011 (suppl; abstr 2505).
14. Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W, Gorecka MA, de Haan AF, Mulders P, Punt CJ, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 2012;35(2):169-78.
15. Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewe R, Nash P, Pricop L, Yuan J, et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med. 2015;373(14):1329-39.